Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)-Reference-Cited by-同舟云学术

Alirocumab and Lipid Levels, Inflammatory Biomarkers, Metabolomics, and Safety in Patients Receiving Maintenance Dialysis: The ALIrocumab in DIALysis Study (A Phase 3 Trial to Evaluate the Efficacy and Safety of Biweekly Alirocumab in Patients on a Stable Dialysis Regimen)

Published:2022-07 Issue:7 Volume:4 Page:100483
ISSN:2590-0595
Container-title:Kidney Medicine
language:en
Short-container-title:Kidney Medicine

Author:

East Cara,Bass Kyle,Mehta Ankit,Rahimighazikalayed Gelareh,Zurawski Sandy,Bottiglieri Teodoro

Publisher

Elsevier BV

Subject

Nephrology,Internal Medicine

Reference14 articles.

1. Racial and survival paradoxes in chronic kidney disease;Kalantar-Zadeh;Nat Clin Pract Nephrol,2007

2. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis;Wanner;N Engl J Med,2005

3. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2 diabetes mellitus on hemodialysis;Krane;Kidney Int,2016

4. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis;Fellström;N Eng J Med,2009

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploratory Research of PCSK9 Inhibitor on Patency of Autogenous Arteriovenous Fistula After Percutaneous Transluminal Angioplasty with Paclitaxel Releasing Balloon: study protocol for a prospective, randomized, controlled trial;2024-08-17

2. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Improves the Vascular Function of Arteriovenous Fistula in Rats with Hyperglycemia;ACTA CARDIOL SIN;2024

3. Proprotein convertase subtilisin/kexin type 9 (PCSK9) and clinical outcomes in patients with end‐stage renal disease;European Journal of Clinical Investigation;2024-06-10

4. Present and Future of Dyslipidaemia Treatment—A Review;Journal of Clinical Medicine;2023-09-08

5. The Anti-Thrombotic Effects of PCSK9 Inhibitors;Pharmaceuticals;2023-08-22